Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Georgetown University
With
GlaxoSmithKline
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
At least one measurable lesion by RECIST criteria
A tumor lesion that can be readily biopsied using a core needle via clinical exam, ultrasound, CT, or fluoroscopic-guidance
Over the age of 18 years and able to provide informed consent
Patients must have progressed after standard therapy for metastatic/ recurrent disease including 5-FU containing regimens for patients with colorectal cancer, and platinum-containing regimens for patients with head and neck cancer and non-small cell lung cancer.
Patients may have received cetuximab, panitumumab or erlotinib previously
Adequate kidney, liver, and bone marrow function
Life expectancy greater than 3 months
ECOG performance status \</= 2
Normal left ventricular ejection fractions
You may not be if
Chemotherapy or surgery within 4 weeks prior to treatment start
Radiation treatment within 3 weeks prior to treatment start
Prior therapy with lapatinib
Untreated brain metastasis or neurologically unstable CNS metastases
Any severe or uncontrolled medical condition or other condition that could affect participation in this study including unstable angina, serious uncontrolled cardiac arrhythmia, uncontrolled infection, or myocardial infarction \</= 6 months prior to study entry
Diarrhea \> grade 1 at baseline
Patients on a medication or herbal therapy known to inhibit CYP3A4
Gastrointestinal tract disease resulting in the inability to take oral medication or a requirement for IV alimentation, prior surgical procedures affecting absorption or active peptic ulcer disease
Ongoing ventricular cardiac dysrhythmias of grade \>/= 2
Subjects with a history of serious ventricular arrhythmia (ventricular tachycardia or ventricular fibrillation \>= 3 beats in a row)
Serious cardiac arrhythmia requiring medication
QTc interval \> 500 msec
Female patients who are pregnant or breast feeding, or adults who are of reproductive potential and are unwilling to refrain from conceiving a child during study treatment
Patients unwilling or unable to comply with the protocol or provide informed consent
Clareo Health | Lapatinib and Cetuximab in Patients With Solid Tumors
